The clinical effect of two thrombolytic regimens in patients with arteriovenous fistula embolism
10.3760/cma.j.issn.1008-1372.2018.06.012
- VernacularTitle:两种溶栓方案治疗动静脉内瘘栓塞患者的疗效观察
- Author:
Fengjuan GU
1
;
Yanzi ZHANG
;
Xiaolu SUI
;
Yunpeng XU
;
Aisha ZHANG
;
Xun SHEN
;
Linghui LIN
;
Yingshan LIU
;
Jihong CHEN
Author Information
1. 南方医科大学附属深圳宝安医院肾内科
- Keywords:
Urokinase-type plasminogen activator/AD;
Heparin,low-molecular-weight/AD;
Arteriovenous fistula;
Arteriovenous fistula/CO;
Thrombosis/CO/DT;
Thrombolytic therapy
- From:
Journal of Chinese Physician
2018;20(6):847-850
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical effect of single urokinase and urokinase pump combined with low-molecular-weight Heparin in the treatment of autogenous arteriovenous fistula thrombolysis,and the influence on inflammatory factors [interleukin (IL)-1,IL-6,tumor necrosis factor-α (TNF-α)] and CD62p.Methods 20 hemodialysis patients hospitalized in our hospital for the treatment of thrombosis in fistula were selected.They were randomly divided into group A (n =10) and group B (n =10).The group A was treated by urokinase infusion,and the group B was treated with urokinase pump combined with low-molecular heparin respectively.Results Compared with that before thrombolysis,the blood flow rate was increased significantly while the IL-1,TNF-oα and CD62p decreased significantly in the two groups after thrombolytic treatment,with statistically significant difference (P ＜ 0.05).Compared with the group A,the IL-1,IL-6 and CD62p in group B were decreased after thrombolytic therapy,with statistically significant difference (P ＜ 0.05).Conclusions Urokinase combined with low-molecular-weight heparin is better than single urokinase in the treatment of arteriovenous fistula thrombolysis,providing a theoretical basis for clinical fistula thrombolysis treatment.
